Raras
Buscar doenças, sintomas, genes...
Linfoma não-Hodgkin indolente de células B
ORPHA:300842DOENÇA RARA

Linfomas de células B são linfomas que afetam linfócitos B, um tipo de leucócito que produz anticorpos. Os sintomas incluem inchaço nos linfonodos, dor abdominal, cansaço, febre, suores noturnos e perda de peso. Os tumores geralmente se iniciam dentro dos linfonodos, do baço, da medula óssea ou no sangue.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Linfoma não-Hodgkin indolente de células B é um câncer de crescimento lento que afeta linfócitos B. Pode causar infecções recorrentes, sangramento gastrointestinal, problemas respiratórios e outros sintomas devido ao acúmulo de células doentes.

Pesquisas ativas
18 ensaios
31 total registrados no ClinicalTrials.gov
Publicações científicas
97 artigos
Último publicado: 2026 Mar 10
Medicamentos
8 registrados
FLUDARABINE PHOSPHATE, RITUXIMAB, OFATUMUMAB

Tem tratamento?

8 medicamentos registrados
Ver detalhes, fases e interações →
FLUDARABINE PHOSPHATERITUXIMABOFATUMUMABIDELALISIBVENETOCLAXACALABRUTINIBACALABRUTINIB MALEATEDUVELISIB MONOHYDRATE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
13 sintomas
🫃
Digestivo
7 sintomas
🧠
Neurológico
4 sintomas
🛡️
Imunológico
3 sintomas
🫁
Pulmão
3 sintomas
👁️
Olhos
3 sintomas

+ 30 sintomas em outras categorias

Características mais comuns

Infecções recorrentes
Hemorragia gastrointestinal
Insuficiência respiratória
Proptose
Edema pedal
Anorexia
73sintomas
Sem dados (73)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 73 características clínicas mais associadas, ordenadas por frequência.

Infecções recorrentesRecurrent infections
Hemorragia gastrointestinalGastrointestinal hemorrhage
Insuficiência respiratóriaRespiratory insufficiency
ProptoseProptosis
Edema pedalPedal edema

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico97PubMed
Últimos 10 anos62publicações
Pico202513 papers
Linha do tempo
2026Hoje · 2026🧪 1996Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

21 genes identificados com associação a esta condição.

MYD88Myeloid differentiation primary response protein MyD88Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response (PubMed:15361868, PubMed:18292575, PubMed:33718825, PubMed:37971847). Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:15361868, PubMed:19506249, PubMed:24316379, PubMed:40638072). Increases IL-8 transcription (PubMed:9013863). Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (9)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingp75NTR recruits signalling complexesInterleukin-1 signalingMyD88:MAL(TIRAP) cascade initiated on plasma membrane
MECANISMO DE DOENÇA

Immunodeficiency 68

An autosomal recessive primary immunodeficiency characterized by life-threatening, often recurrent, pyogenic bacterial infections, including invasive pneumococcal disease, beginning in infancy or early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
199.5 TPM
Baço
107.2 TPM
Linfócitos
92.5 TPM
Pulmão
69.5 TPM
Esôfago - Mucosa
63.7 TPM
OUTRAS DOENÇAS (4)
pyogenic bacterial infections due to MyD88 deficiencymacroglobulinemia, Waldenstrom, 1immunodeficiency 67Waldenstrom macroglobulinemia
HGNC:7562UniProt:Q99836
MALT1Mucosa-associated lymphoid tissue lymphoma translocation protein 1Candidate gene tested inRestrito
FUNÇÃO

Protease that enhances BCL10-induced activation: acts via formation of CBM complexes that channel adaptive and innate immune signaling downstream of CARD domain-containing proteins (CARD9, CARD11 and CARD14) to activate NF-kappa-B and MAP kinase p38 pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:11262391, PubMed:18264101, PubMed:24074955). Mediates BCL10 cleavage: MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen rec

LOCALIZAÇÃO

Cytoplasm, perinuclear regionNucleus

VIAS BIOLÓGICAS (5)
Downstream TCR signalingCLEC7A (Dectin-1) signalingFCERI mediated NF-kB activationCLEC7A/inflammasome pathwayActivation of NF-kappaB in B cells
MECANISMO DE DOENÇA

Immunodeficiency 12

A primary immunodeficiency characterized by onset in infancy of recurrent bacterial and candidal infections resulting in bronchiectasis and growth delay. Manifestations include mastoiditis, aphthous ulcers, cheilitis, gingivitis, esophagitis, gastritis, duodenitis, and meningitis. Levels of absolute lymphocytes and serum immunoglobulins are normal, but specific antibody titers are low despite immunization, and T-cells show impaired proliferative responses to mitogens.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
45.8 TPM
Próstata
21.0 TPM
Vagina
16.7 TPM
Esôfago - Mucosa
14.3 TPM
Skin Sun Exposed Lower leg
13.9 TPM
OUTRAS DOENÇAS (2)
combined immunodeficiency due to MALT1 deficiencyMALT lymphoma
HGNC:6819UniProt:Q9UDY8
BIRC3Baculoviral IAP repeat-containing protein 3Candidate gene tested inTolerante
FUNÇÃO

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canon

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
NOD1/2 Signaling PathwayIKK complex recruitment mediated by RIP1TICAM1, RIP1-mediated IKK complex recruitmentRIPK1-mediated regulated necrosisTNFR1-induced proapoptotic signaling
OUTRAS DOENÇAS (1)
MALT lymphoma
HGNC:591UniProt:Q13489
FOXP1Forkhead box protein P1Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional repressor (PubMed:18347093, PubMed:26647308). Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential (By similarity). Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. I

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Transcriptional regulation of pluripotent stem cells
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
32.4 TPM
Esôfago - Junção
30.3 TPM
Aorta
27.7 TPM
Artéria tibial
27.1 TPM
Cólon sigmoide
26.3 TPM
OUTRAS DOENÇAS (3)
intellectual disability-severe speech delay-mild dysmorphism syndromeB-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalityMALT lymphoma
HGNC:3823UniProt:Q9H334
ARL11ADP-ribosylation factor-like protein 11Candidate gene tested inDesconhecido
FUNÇÃO

May play a role in apoptosis. May act as a tumor suppressor

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Leukemia, chronic lymphocytic

A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
B-cell chronic lymphocytic leukemia
HGNC:24046UniProt:Q969Q4
IKZF3Zinc finger protein AiolosCandidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Immunodeficiency 84

An autosomal recessive immunologic disorder characterized by recurrent sinopulmonary infections from childhood associated with low levels of B cells and impaired early B-cell development. There may also be variable T-cell abnormalities. Patients have increased susceptibility to infection with Epstein-Barr virus and a propensity for the development of lymphoma in adulthood.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
69.4 TPM
Baço
36.8 TPM
Intestino delgado
11.3 TPM
Sangue
6.3 TPM
Pulmão
5.0 TPM
OUTRAS DOENÇAS (2)
immunodeficiency 84B-cell chronic lymphocytic leukemia
HGNC:13178UniProt:Q9UKT9
RPS15Small ribosomal subunit protein uS19Candidate gene tested inRestrito
FUNÇÃO

Component of the small ribosomal subunit (PubMed:23636399). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1394.1 TPM
Skin Not Sun Exposed Suprapubic
1062.7 TPM
Linfócitos
1011.1 TPM
Skin Sun Exposed Lower leg
998.3 TPM
Cervix Ectocervix
926.8 TPM
OUTRAS DOENÇAS (1)
B-cell chronic lymphocytic leukemia
HGNC:10388UniProt:P62841
IGHV4-34Immunoglobulin heavy variable 4-34Candidate gene tested inDesconhecido
FUNÇÃO

V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secr

LOCALIZAÇÃO

SecretedCell membrane

VIAS BIOLÓGICAS (10)
Role of phospholipids in phagocytosisFCGR3A-mediated IL10 synthesisRegulation of actin dynamics for phagocytic cup formationFCGR activationInitial triggering of complement
EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
185.6 TPM
Glândula salivar
70.3 TPM
Cólon transverso
41.0 TPM
Intestino delgado
39.8 TPM
Pulmão
25.2 TPM
OUTRAS DOENÇAS (1)
hairy cell leukemia variant
HGNC:5650UniProt:P06331
IGHG1Immunoglobulin heavy constant gamma 1Candidate gene tested inDesconhecido
FUNÇÃO

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellula

LOCALIZAÇÃO

SecretedCell membrane

VIAS BIOLÓGICAS (9)
Role of phospholipids in phagocytosisFCGR3A-mediated IL10 synthesisRegulation of actin dynamics for phagocytic cup formationFCGR activationInitial triggering of complement
MECANISMO DE DOENÇA

Multiple myeloma

A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
3470.1 TPM
Pulmão
294.7 TPM
Linfócitos
260.7 TPM
Fallopian Tube
212.2 TPM
Intestino delgado
201.6 TPM
OUTRAS DOENÇAS (2)
systemic lupus erythematosusB-cell chronic lymphocytic leukemia
HGNC:5525UniProt:P01857
BCL2Apoptosis regulator Bcl-2Candidate gene tested inAltamente restrito
FUNÇÃO

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells (PubMed:1508712, PubMed:8183370). Regulates cell death by controlling the mitochondrial membrane permeability (PubMed:11368354). Appears to function in a feedback loop system with caspases (PubMed:11368354). Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) (PubMed:11368354).

LOCALIZAÇÃO

Mitochondrion outer membraneNucleus membraneEndoplasmic reticulum membraneCytoplasm

VIAS BIOLÓGICAS (8)
The NLRP1 inflammasomeInterleukin-4 and Interleukin-13 signalingBH3-only proteins associate with and inactivate anti-apoptotic BCL-2 membersActivation of BAD and translocation to mitochondria Estrogen-dependent nuclear events downstream of ESR-membrane signaling
OUTRAS DOENÇAS (3)
follicular lymphomaintravascular large B-cell lymphomahigh grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
HGNC:990UniProt:P10415
CCND1G1/S-specific cyclin-D1Candidate gene tested inRestrito
FUNÇÃO

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:1827756, PubMed:1833066, PubMed:19412162, PubMed:33854235, PubMed:8114739, PubMed:8302605). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression

LOCALIZAÇÃO

NucleusCytoplasmNucleus membrane

VIAS BIOLÓGICAS (9)
Cyclin D associated events in G1PTK6 Regulates Cell CycleSCF(Skp2)-mediated degradation of p27/p21SPOP-mediated proteasomal degradation of PD-L1(CD274)Transcriptional Regulation by VENTX
OUTRAS DOENÇAS (5)
B-cell chronic lymphocytic leukemiaplasma cell myelomavon Hippel-Lindau diseasemantle cell lymphoma
HGNC:1582UniProt:P24385
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainCandidate gene tested inRestrito
FUNÇÃO

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneLysosome membraneLate endosome membraneAutolysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911
POT1Protection of telomeres protein 1Candidate gene tested inTolerante
FUNÇÃO

Component of the telomerase ribonucleoprotein (RNP) complex that is essential for the replication of chromosome termini. Is a component of the double-stranded telomeric DNA-binding TRF1 complex which is involved in the regulation of telomere length by cis-inhibition of telomerase. Also acts as a single-stranded telomeric DNA-binding protein and thus may act as a downstream effector of the TRF1 complex and may transduce information about telomere maintenance and/or length to the telomere terminus

LOCALIZAÇÃO

NucleusChromosome, telomere

VIAS BIOLÓGICAS (10)
DNA Damage/Telomere Stress Induced SenescencePackaging Of Telomere EndsMeiotic synapsisInhibition of DNA recombination at telomereTelomere C-strand (Lagging Strand) Synthesis
MECANISMO DE DOENÇA

Tumor predisposition syndrome 3

An autosomal dominant disorder characterized by an increased risk for the development of various types of benign and malignant neoplasms throughout life, with age-dependent penetrance. Affected individuals can develop neoplasms involving epithelial, mesenchymal, and neuronal tissues, as well as lymphoid and myeloid cancers. The disorder is associated with elongated telomeres.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.7 TPM
Nervo tibial
15.9 TPM
Testículo
15.3 TPM
Cervix Ectocervix
13.7 TPM
Útero
13.5 TPM
OUTRAS DOENÇAS (7)
tumor predisposition syndrome 3pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8cerebroretinal microangiopathy with calcifications and cysts 3oligodendroglioma
HGNC:17284UniProt:Q9NUX5
P2RX7P2X purinoceptor 7Candidate gene tested inTolerante
FUNÇÃO

ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small cations Na(+) and Ca(2+), and the K(+) efflux (PubMed:17483156, PubMed:20453110, PubMed:28235784, PubMed:39262850). Also has the ability to form a large pore in the cell membrane, allowing the passage of large cationic molecules (PubMed:17483156). In microglia, may

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (5)
The NLRP3 inflammasomeMechanical load activates signaling by PIEZO1 and integrins in osteocytesPurinergic signaling in leishmaniasis infectionElevation of cytosolic Ca2+ levelsPlatelet homeostasis
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
29.1 TPM
Skin Sun Exposed Lower leg
19.2 TPM
Cervix Ectocervix
16.4 TPM
Skin Not Sun Exposed Suprapubic
16.3 TPM
Nervo tibial
16.3 TPM
OUTRAS DOENÇAS (1)
B-cell chronic lymphocytic leukemia
HGNC:8537UniProt:Q99572
BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
IGHCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Role of phospholipids in phagocytosisFCGR3A-mediated IL10 synthesisRegulation of actin dynamics for phagocytic cup formationFCGR activationInitial triggering of complement
OUTRAS DOENÇAS (4)
follicular lymphomaMALT lymphomaB-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3)mantle cell lymphoma
HGNC:5477
IGHV3-21Immunoglobulin heavy variable 3-21Candidate gene tested inDesconhecido
FUNÇÃO

V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secr

LOCALIZAÇÃO

SecretedCell membrane

VIAS BIOLÓGICAS (10)
Role of phospholipids in phagocytosisFCGR3A-mediated IL10 synthesisRegulation of actin dynamics for phagocytic cup formationFCGR activationInitial triggering of complement
EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
281.7 TPM
Glândula salivar
172.7 TPM
Cólon transverso
107.4 TPM
Intestino delgado
81.2 TPM
Pulmão
34.7 TPM
OUTRAS DOENÇAS (1)
B-cell chronic lymphocytic leukemia
HGNC:5586UniProt:A0A0B4J1V1
ATMSerine-protein kinase ATMCandidate gene tested inTolerante
FUNÇÃO

Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). Recognizes the substrate c

LOCALIZAÇÃO

NucleusCytoplasmic vesicleCytoplasm, cytoskeleton, microtubule organizing center, centrosomePeroxisome matrix

VIAS BIOLÓGICAS (5)
DNA Damage/Telomere Stress Induced SenescenceSensing of DNA Double Strand BreaksTP53 Regulates Transcription of DNA Repair GenesMeiotic recombinationRegulation of HSF1-mediated heat shock response
MECANISMO DE DOENÇA

Ataxia telangiectasia

A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.

OUTRAS DOENÇAS (9)
ataxia telangiectasiaATM-related cancer predispositionfamilial colorectal cancer type XB-cell chronic lymphocytic leukemia
HGNC:795UniProt:Q13315
BCL6B-cell lymphoma 6 proteinCandidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertainFOXO-mediated transcription of cell death genesInterleukin-4 and Interleukin-13 signaling
OUTRAS DOENÇAS (4)
follicular lymphomaprimary mediastinal large B-cell lymphomaintravascular large B-cell lymphomahigh grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
HGNC:1001UniProt:P41182
BCL10B-cell lymphoma/leukemia 10Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation (PubMed:10187770, PubMed:10364242, PubMed:10400625, PubMed:24074955, PubMed:25365219). Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokin

LOCALIZAÇÃO

Cytoplasm, perinuclear regionMembrane raft

VIAS BIOLÓGICAS (4)
Downstream TCR signalingFCERI mediated NF-kB activationCLEC7A (Dectin-1) signalingE3 ubiquitin ligases ubiquitinate target proteins
OUTRAS DOENÇAS (5)
MALT lymphomaimmunodeficiency 37testicular germ cell tumorlymphoma, non-Hodgkin, familial
HGNC:989UniProt:O95999

Medicamentos e terapias

FLUDARABINE PHOSPHATEPhase 4

Mecanismo: DNA polymerase (alpha/delta/epsilon) inhibitor

RITUXIMABPhase 4

Mecanismo: B-lymphocyte antigen CD20 binding agent

OFATUMUMABPhase 4

Mecanismo: B-lymphocyte antigen CD20 binding agent

IDELALISIBPhase 4

Mecanismo: PI3-kinase p110-delta subunit inhibitor

VENETOCLAXPhase 4

Mecanismo: Apoptosis regulator Bcl-2 inhibitor

ACALABRUTINIBPhase 4

Mecanismo: Tyrosine-protein kinase BTK inhibitor

ACALABRUTINIB MALEATEPhase 4

Mecanismo: Tyrosine-protein kinase BTK inhibitor

DUVELISIB MONOHYDRATEPhase 4

Mecanismo: PI3-kinase p110-gamma subunit inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

156 variantes patogênicas registradas no ClinVar.

🧬 MYD88: GRCh37/hg19 3p26.3-14.3(chr3:2263690-55016039)x3 ()
🧬 MYD88: NC_000003.11:g.(?_38180153)_(38182777_?)del ()
🧬 MYD88: NM_002468.5(MYD88):c.256_257del (p.Val86fs) ()
🧬 MYD88: NM_002468.5(MYD88):c.463+1G>A ()
🧬 MYD88: NC_000003.11:g.(?_16710965)_(41275270_?)del ()
Ver todas no ClinVar

Vias biológicas (Reactome)

196 vias biológicas associadas aos genes desta condição.

ER-Phagosome pathway PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane RIP-mediated NFkB activation via ZBP1 p75NTR recruits signalling complexes DEx/H-box helicases activate type I IFN and inflammatory cytokines production MyD88 deficiency (TLR2/4) MyD88 deficiency (TLR5) IRAK4 deficiency (TLR5) IRAK4 deficiency (TLR2/4) PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Interleukin-1 signaling TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane Activation of NF-kappaB in B cells Downstream TCR signaling FCERI mediated NF-kB activation CLEC7A (Dectin-1) signaling CLEC7A/inflammasome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIPK1-mediated regulated necrosis TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR2 non-canonical NF-kB pathway Regulation of necroptotic cell death TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway Ub-specific processing proteases IKK complex recruitment mediated by RIP1 Transcriptional regulation of pluripotent stem cells CRBN binds IMiDs L13a-mediated translational silencing of Ceruloplasmin expression Peptide chain elongation SRP-dependent cotranslational protein targeting to membrane Viral mRNA Translation Selenocysteine synthesis Major pathway of rRNA processing in the nucleolus and cytosol Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Eukaryotic Translation Termination Regulation of expression of SLITs and ROBOs Response of EIF2AK4 (GCN2) to amino acid deficiency SARS-CoV-1 modulates host translation machinery SARS-CoV-2 modulates host translation machinery Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA Initial triggering of complement Classical antibody-mediated complement activation Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Cell surface interactions at the vascular wall FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Scavenging of heme from plasma Fc epsilon receptor (FCERI) signaling Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization CD22 mediated BCR regulation FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Potential therapeutics for SARS Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Interleukin-4 and Interleukin-13 signaling Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members The NLRP1 inflammasome Estrogen-dependent gene expression Estrogen-dependent nuclear events downstream of ESR-membrane signaling NFE2L2 regulating tumorigenic genes Regulation of MITF-M-dependent genes involved in apoptosis SCF(Skp2)-mediated degradation of p27/p21 Pre-NOTCH Transcription and Translation RMTs methylate histone arginines Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional Regulation by VENTX Transcriptional regulation by RUNX2 Regulation of RUNX1 Expression and Activity RUNX3 regulates WNT signaling RUNX3 regulates p14-ARF Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity Regulation of MITF-M-dependent genes involved in cell cycle and proliferation SPOP-mediated proteasomal degradation of PD-L1(CD274) Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules MHC class II antigen presentation Co-inhibition by PD-1 Interferon gamma signaling Recognition and association of DNA glycosylase with site containing an affected pyrimidine Cleavage of the damaged pyrimidine Recognition and association of DNA glycosylase with site containing an affected purine Cleavage of the damaged purine Meiotic synapsis Packaging Of Telomere Ends Telomere Extension By Telomerase Polymerase switching on the C-strand of the telomere Processive synthesis on the C-strand of the telomere Telomere C-strand (Lagging Strand) Synthesis Telomere C-strand synthesis initiation Removal of the Flap Intermediate from the C-strand DNA Damage/Telomere Stress Induced Senescence Inhibition of DNA recombination at telomere Elevation of cytosolic Ca2+ levels Platelet homeostasis The NLRP3 inflammasome Purinergic signaling in leishmaniasis infection Mechanical load activates signaling by PIEZO1 and integrins in osteocytes Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation t(4;14) translocations of FGFR3 FGFR3 mutant receptor activation Signaling by FGFR3 in disease Interleukin-21 signaling Defective CYP21A2 causes AH3 Intestinal infectious diseases Regulation of PTEN mRNA translation Extra-nuclear estrogen signaling Signaling by CSF1 (M-CSF) in myeloid cells PTEN Regulation Small interfering RNA (siRNA) biogenesis Defective CYP11B1 causes AH4 MPS VII - Sly syndrome (CS/DS degradation) Regulation of HSF1-mediated heat shock response HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange G2/M DNA damage checkpoint Stabilization of p53 Meiotic recombination Pexophagy Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2 FOXO-mediated transcription of cell death genes E3 ubiquitin ligases ubiquitinate target proteins

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado8
3Fase 31
2Fase 211
1Fase 18
Medicamentos catalogadosEnsaios clínicos· 8 medicamentos · 20 ensaios
✓ Aprovados — podem ser usados hoje
FLUDARABINE PHOSPHATERITUXIMABOFATUMUMABIDELALISIBVENETOCLAXACALABRUTINIBACALABRUTINIB MALEATEDUVELISIB MONOHYDRATE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Linfoma não-Hodgkin indolente de células B

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

11 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

31 ensaios clínicos encontrados, 18 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
63 papers (10 anos)
#1

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

British journal of haematology2026 Mar 10
#2

A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.

Diagnostics (Basel, Switzerland)2025 Oct 21

Background and Clinical Significance: Waldenström macroglobulinemia (WM) is a rare, indolent B-cell non-Hodgkin lymphoma, characterised by the presence of monoclonal immunoglobulin M (IgM) and lymphoplasmacytic infiltration of the bone marrow. It is often associated with various haematological and systemic disorders, including previous cold agglutinin disease (CAD), a condition where cold-sensitive antibodies lead to haemolysis. Case Presentation: A 55-year-old male patient was admitted to the Internal Diseases Ward with symptoms of weakness, reduced effort tolerance, and weight loss, along with life-threatening normoblastic anaemia (haemoglobin [Hb]: 3.90 g/dL). Initial blood tests raised suspicion of CAD due to the presence of multiple blood clots, as well as a decrease in lymphocyte and neutrophil counts. CAD was then confirmed by a cold agglutinin titre of 1:2000 and direct antiglobulin test ([DAT] 4+). Two weeks later, upon transfer to the Haematological Diseases Ward, further investigation revealed elevated IgM levels (up to 31.55 g/L). Additional diagnostic tests, including serum protein electrophoresis, imaging, multiparametric flow cytometry, and bone marrow biopsy, confirmed the diagnosis of WM. The L265P MYD88 mutation test was positive. Treatment with intravenous rituximab was initiated, followed by bendamustine/rituximab (BR) therapy protocol as first-line treatment. After two cycles, the patient's clinical condition and laboratory results significantly improved, with a marked reduction in IgM (<0.4 g/L). Hb levels steadily rose to 12.60 g/dL, eliminating the need for further blood transfusions. Conclusions: This case highlights the importance of recognising the coexistence of CAD and WM, which may present with overlapping clinical features, including life-threatening anaemia. Extensive diagnostics and prompt treatment with combination therapy can lead to effective clinical improvement.

#3

[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025 Sep 14

Objective: To investigate the efficacy and safety of bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma (B-iNHL) . Methods: The clinical data of 159 patients with B-iNHL enrolled in 16 hospitals from Jiangsu Cooperative Lymphoma Group from December 1, 2019, to April 20, 2024, were analyzed for regimen efficacy and safety. Bendamustine plus rituximab (BR) and bendamustine plus obinutuzumab (BG) were administered to 139 (87.4% ) and 20 (12.6% ) patients, respectively. Results: Among the 159 patients, 101 (63.5% ) were male and 58 (36.5% ) were female, with a median age of 69 years (range: 60-84). Efficacy could be assessed in 138 (86.8% ) patients. The efficacy assessment demonstrated that the overall response rate was 92.0% with complete and partial remissions in 75 (54.3% ) and 52 (37.7% ) cases, respectively. With a median follow-up of 24 months (range: 4-64), the progression-free survival rate was (87.5 ± 3.0) % and the overall survival rate was (83.2 ± 3.3) %. Of the 27 patients who died, 6 (22.2% ) died due to disease progression. The mean applied dose of bendamustine per cycle was 73.0 (50.8-89.7) mg/m(2) per day, administered on days 1 and 2. Adverse events of grade 3 or higher were reported in 53 (33.3% ) patients, with infection (30 cases,18.9% ) and neutropenia (24 cases, 15.1% ) demonstrating the highest incidence. Conclusion: Bendamustine combined with anti-CD20 monoclonal antibody demonstrated good efficacy and is well-tolerated in the first-line treatment of elderly patients with B-iNHL. 目的: 评估苯达莫司汀联合抗CD20单抗一线治疗老年惰性B细胞非霍奇金淋巴瘤(B-iNHL)患者的疗效与安全性。 方法: 回顾性分析2019年12月1日至2024年4月20日期间在江苏省淋巴瘤协作组16家医院就诊的159例老年B-iNHL患者应用苯达莫司汀联合抗CD20单抗(利妥昔单抗或奥妥珠单抗)治疗的疗效及安全性。其中139例(87.4%)应用BR(苯达莫司汀+利妥昔单抗)方案治疗,20例(12.6%)应用BG(苯达莫司汀+奥妥珠单抗)方案治疗。 结果: 159例患者中男101例(63.5%)、女58例(36.5%),中位年龄为69(60~84)岁。138例(86.8%)患者可评估疗效,其中75例(54.3%)患者达完全缓解,52例(37.7%)患者达部分缓解,总有效率为92.0%。中位随访24(4~64)个月,患者无进展生存率为(87.5±3.0)%,总生存率为(83.2±3.3)%。死亡的27例患者中,仅6例(22.2%)伴有疾病进展。每周期苯达莫司汀中位应用剂量为73.0(50.8~89.7)mg·m(-2)·d(-1),第1、2天用药。53例(33.3%)患者出现3级及以上的不良反应,感染(30例,18.9%)发生率最高,其次是中性粒细胞减少(24例,15.1%)。 结论: 真实世界老年B-iNHL患者一线应用苯达莫司汀联合抗CD20单抗疗效较好,安全性可控,耐受性较好。.

#4

The emerging role of tafasitamab in follicular lymphoma.

Leukemia &amp; lymphoma2025 Dec

Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma, characterized by recurrent relapses, risk of histologic transformation, and heterogeneous clinical outcomes. Despite advances with novel therapies, the management of relapsed/refractory FL remains challenging. Tafasitamab, a humanized anti-CD19 monoclonal antibody, is currently approved, in combination with lenalidomide, for relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and together with lenalidomide and rituximab for R/R FL. Clinical trial data support its efficacy and manageable safety profile in FL starting from fisrt relapse, including in high-risk FL subgroups such as early relapse (POD24) and CD20-refractory disease. This chemotherapy-free regiment is added with its favorable safety profile to more complex therapies such as CAR T-cell therapy or bispecific antibodies. Further studies are needed to clarify tafasitamab's durability of benefit, optimal sequencing, and integration within the evolving FL treatment landscape.

#5

Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.

Journal of medicine and life2025 Jul

Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an acquired immune-mediated neuropathy characterized by progressive or relapsing-remitting proximal and distal weakness. Lymphomas are among various hematological malignancies associated with CIDP. Splenic marginal zone lymphoma (SMZL) is a rare, indolent B-cell non-Hodgkin lymphoma that classically presents with splenomegaly and cytopenia. The co-occurrence of SMZL and CIDP is extremely rare; the diagnosis thus presents a unique challenge both diagnostically and therapeutically. We report a 65-year-old male patient with progressive proximal weakness, night sweats, and splenomegaly. Investigations revealed pancytopenia with imaging studies confirming the splenomegaly. Further investigations, such as a bone marrow biopsy and histopathology of the spleen, were indicative of a hypocellular marrow and SMZL, respectively. Simultaneously, a diagnosis of CIDP was established based on clinical findings, as well as electromyography and nerve conduction studies. For CIDP, immunosuppressive therapy was initiated; however, no treatment was administered for SMZL due to its indolent nature. He showed partial neurological improvement with the treatment given for CIDP. This underlines the importance of treating both diseases. The rare association of CIDP and SMZL is presented in this case, highlighting the importance of a comprehensive diagnostic workup in patients with neurological and hematological abnormalities. Therefore, for the management of such patients, timely identification and appropriate therapeutic approaches will be necessary for an improved outcome.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC35 artigos no totalmostrando 61

2026

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

British journal of haematology
2025

A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response.

Diagnostics (Basel, Switzerland)
2025

[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2025

The emerging role of tafasitamab in follicular lymphoma.

Leukemia &amp; lymphoma
2025

Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.

Journal of medicine and life
2025

Identifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression.

Expert review of hematology
2025

Long-acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine-treated patients with indolent B cell non-Hodgkin lymphoma: a multicentric real-life experience.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2025

Chimeric antigen receptor T-cell therapy in aggressive lymphomas.

Current opinion in oncology
2025

Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment.

Hematological oncology
2025

[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].

Radiologie (Heidelberg, Germany)
2025

Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study.

Annals of hematology
2025

An Autopsy Case of Bronchiolitis Obliterans Associated With Oral Lichen Planus and Non-Hodgkin Lymphoma.

Cureus
2025

Concurrent papillary thyroid carcinoma and incidental cervical lymph node indolent B cell non-Hodgkin lymphoma: clinicopathological features, outcomes, and potential relationships.

World journal of surgical oncology
2025

Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.

Current treatment options in oncology
2024

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.

EClinicalMedicine
2024

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

Transplantation and cellular therapy
2024

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database.

Frontiers in pharmacology
2024

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.

Hematological oncology
2024

Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.

Leukemia &amp; lymphoma
2023

Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?

Cancers
2023

[Expert Consensus on the prevention and treatment of indolent B-cell non-Hodgkin lymphoma with novel coronavirus infection].

Zhonghua yi xue za zhi
2023

[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2023

Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.

Cancer
2023

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.

Blood advances
2022

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.

Clinical pharmacology in drug development
2022

A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.

Cancer chemotherapy and pharmacology
2022

Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).

Oncology reports
2021

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.

Journal of hematology &amp; oncology
2021

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.

Chinese medical journal
2021

Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature.

Journal of hematology
2020

Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.

Japanese journal of clinical oncology
2020

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.

Blood advances
2020

Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.

Cancer medicine
2020

High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result.

European journal of haematology
2019

Where does transplant fit in the age of targeted therapies?

Hematology. American Society of Hematology. Education Program
2019

Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets.

BMC infectious diseases
2019

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

International journal of hematology
2019

MALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric Tumor Development.

Current topics in microbiology and immunology
2019

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

JCI insight
2019

The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.

Molecular carcinogenesis
2019

Burden of illness of follicular lymphoma and marginal zone lymphoma.

Annals of hematology
2017

T follicular helper cells: a potential therapeutic target in follicular lymphoma.

Oncotarget
2018

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.

Clinical lymphoma, myeloma &amp; leukemia
2017

Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.

Journal of clinical pharmacology
2017

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

International journal of hematology
2016

B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.

The American journal of pathology
2016

Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.

International journal of hematology
2016

The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.

Expert opinion on drug discovery
2017

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2016

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.

British journal of haematology
2016

A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.

British journal of haematology
2015

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

The Lancet. Haematology
2015

Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.

BMC cancer
2015

Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation.

Current opinion in hematology
2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2015

Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Expert review of anticancer therapy
2015

Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma.

PloS one
2015

Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.

Cancer chemotherapy and pharmacology
2015

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

Future oncology (London, England)
2015

A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.

International journal of hematology
2015

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.

Haematologica

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Linfoma não-Hodgkin indolente de células B.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Linfoma não-Hodgkin indolente de células B

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
    British journal of haematology· 2026· PMID 41806221mais citado
  2. A Rare Combination: Cold Agglutinin Disease Followed by Waldenstr&#xf6;m Macroglobulinemia-A Case of Early Treatment Response.
    Diagnostics (Basel, Switzerland)· 2025· PMID 41153326mais citado
  3. [Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi· 2025· PMID 41145285mais citado
  4. The emerging role of tafasitamab in follicular lymphoma.
    Leukemia &amp; lymphoma· 2025· PMID 41090546mais citado
  5. Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.
    Journal of medicine and life· 2025· PMID 40893811mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:300842(Orphanet)
  2. MONDO:0017594(MONDO)
  3. GARD:21244(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787211(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Linfoma não-Hodgkin indolente de células B
Compêndio · Raras BR

Linfoma não-Hodgkin indolente de células B

ORPHA:300842 · MONDO:0017594
Prevalência
Unknown
Ensaios
18 ativos
Medicamentos
8 registrados
Início
Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C5419078
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades